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ABSTRACT
Objective: Langerhans cell histiocytosis (LCH) is an uncommon entity of unknown etiology. It contains a wide range 
of clinical presentations. The discovery of oncogenic BRAF V600E mutation in LCH has provided additional evidence 
that LCH is a neoplasm. Papillary thyroid carcinoma is the most common cancer of the thyroid characterized by a high 
incidence of BRAF V600E mutations. LCH with concomitant PTC is rare, with few cases reported in the literature. Cases 
summary: We identified two cases of LCH with concomitant papillary thyroid carcinoma in adult patients. The first was 
a 49-year-old female with a thyroid nodule diagnosed with papillary thyroid carcinoma. Later, the patient had a left neck 
mass; Ultrasound-guided lymph node FNA was diagnosed with Langerhans histiocytosis. Subsequently, a chest CT scan 
revealed signs of Langerhans cell histiocytosis in the lung. The second case refers to a 69-year-old male who presented 
with a left thyroid nodule diagnosed on FNA cytology as papillary thyroid carcinoma. The patient was found to have 
multiple bone lytic lesions. Biopsies revealed Langerhans cell histiocytosis. Later, the patient experienced LCH involvement 
of the bone marrow with associated secondary myelofibrosis. Conclusions: LCH is rare in adults; the association with 
papillary thyroid carcinoma is reported and should be considered in the presence of Langerhans cell groups along with 
PTC, whether in the thyroid gland or cervical lymph nodes. Once LCH has been diagnosed, pulmonary involvement 
should also be investigated. This will direct treatment plans for patients with pulmonary or systemic disease involvement. 
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INTRODUCTION
Langerhans cell histiocytosis (LCH) involves 
various clinical disorders that share Langerhans 
cel ls ’  prol i ferat ion with typical  morphology, 
immunophenotype, and ultrastructural characteristics.1 
The estimated annual incidence is approximately 
5 cases per 1 million population, with most cases 
occurring in childhood.2 For therapeutic purposes, 
patterns of involvement are typically stratified into 
single-system LCH and multisystem LCH.3
As Langerhans cell histiocytosis (LCH) is rare in 
adults (detected in one to two adults per 1 million 
populations),4 it is challenging to associate clinical 
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features with prognosis, ideal treatment, and a usual 
history.5 In comparison to childhood LCH, there is 
a lack of explicit evidence-based references and 
recommendations. Unlike childhood LCH, a rapidly 
progressive form is typically not observed in adults. 
The usual presentation is with a unifocal disease, most 
often a lytic bone lesion or solitary lesions at other sites 
with enlarged lymph nodes.6
Isolated lung involvement is a special type of 
LCH that almost always occurs in adult smokers in 
their third and fourth decades. While adult LCH is 
sometimes considered a pulmonary disorder, it may 
present with isolated extrapulmonary manifestations.5 
The most common non-pulmonary locations include 
the bone, skin, and pituitary gland and less frequently 
the lymph nodes, liver, spleen, gut, and central nervous 
system (CNS).6 The bone marrow is rarely involved in 
adults, as opposed to children.7 The thyroid gland may 
occasionally be involved in LCH, but isolated thyroid 
LCH is extremely rare. Thyroid involvement is more 
frequently reported in adults than in children with a 
slight female predominance.8
While papillary thyroid carcinoma (PTC) is the 
most common cancer of the thyroid gland, these two 
entities’ co-existence in the thyroid gland is unusual 
and reported only in a few cases available in the 
literature.
Herein, we report two cases of LCH with 
concomitant papillary thyroid carcinoma in adult 
patients.
MATERIAL AND METHODS
In the Department of Pathology at the King 
Hussein Cancer Center, we identified two Langerhans 
cell histiocytosis cases in conjunction with papillary 
thyroid carcinoma. Preoperative thyroid ultrasound and 
cytology FNA smears were available in each case. The 
excised tissue was serially sectioned and fixed in 10% 
buffered formalin overnight. The sections taken were 
routinely processed for paraffin embedding and were 
stained using hematoxylin and eosin. Immunostaining 
was performed on the paraffin-embedded material 
using the avidin-biotin complex protocol with an 
iVIEW DAB detection kit (Ventana Medical Systems). 
Monoclonal antibodies against CDIa (EP3622,Ventana), 
S100 (Polyclonal, Ventana) and CD68 (KP-1,Ventana) 
were used in both cases. All immunostains were 
performed on the Ventana Benchmark XT automated 
immunostainer.
We conducted a literature review via PubMed. 
We searched for the English language published case 
series and case reports on adults with concomitant 
Langerhans cell histiocytosis and papillary thyroid 
carcinoma. The year of publication was limited to 
1990 onwards.
CASE 1
A 49-year-old female patient was diagnosed with 
a thyroid nodule on routine neck ultrasound; she had 
no family history of thyroid cancer. Laboratory tests 
showed euthyroidism. Neck ultrasound revealed partly 
cystic and hypoechoic nodules in both thyroid lobes, 
the largest of which was 10 x 8 x 15 mm in the right 
lobe. No enlarged neck lymph nodes were identified.
Ultrasound-guided FNA was performed and 
interpreted as suspicious for papillary thyroid carcinoma, 
and a total thyroidectomy was undertaken. The thyroid 
gland was received intact. Serial sectioning revealed 
multiple nodules. The tumor was identified in the 
right lobe, measuring 0.3x0.2x0.1cm. Microscopic 
examination revealed classic papil lary thyroid 
microcarcinoma in multi-nodular goiter (Figure 1A).
The patient was discharged after a week and 
scheduled for close follow-up.
Five months later, the patient presented with 
odynophagia. Physical examination showed a left neck 
mass, which on the ultrasound examination consisted 
of an enlarged rounded cortically thickened left level II 
lymph node measuring 1.5 x 2.5 cm, likely metastatic, 
with few smaller yet pathological left level Ib and II 
lymph nodes. Ultrasound-guided lymph node FNA 
was done. The smears showed cells with reniform 
nuclei and abundant eosinophilic cytoplasm. The 
nuclei displayed prominent grooving but no nuclear 
pseudoinclusions (Figure 1B). Many eosinophils were 
seen in the background. These cells were positive for 
CD68 and CD1a (Figure 1C and 1D) and negative for 
S100, ERG, and TTF1.
The diagnosis was consistent with Langerhans 
cell histiocytosis. Subsequently, a chest CT scan was 
performed and revealed small pulmonary nodules 
and cysts affecting both lungs, primarily seen in the 
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Figure 1. A – Thyroid gland with classic papillary thyroid carcinoma (H&E,40x); B – Cytologic preparation showing 
cells with reniform nuclei and abundant eosinophilic cytoplasm, the nuclei show prominent grooving (Arrows) (PAP 
stain 40x); C and D – Positivity for CD68 and CD1a immunostains, respectively done on the cell block (20x).
lower lobes, likely due to pulmonary Langerhans cell 
histiocytosis (Figure 2). After three months, the Chest CT 
scan showed unchanged bilateral pulmonary nodules 
with no mediastinal or axillary lymphadenopathy, and 
the bone scan revealed nonspecific lytic lesions within 
the proximal right femoral shaft. The patient was asked 
to stop smoking, and she was scheduled for a regular 
follow up CT scan every three months.
CASE 2
A 69-year-old male presented a left thyroid 
nodule diagnosed on FNA cytology as papillary thyroid 
carcinoma. During investigations, the patient was 
found to have multiple bone lytic lesions. Biopsies 
of the lumbar vertebra and left clavicle showed 
Langerhans cell histiocytosis. The patient underwent 
total thyroidectomy with left cervical lymph node 
dissection. Sectioning of the specimen revealed 
two lesions in the right thyroid lobe measuring 
3.7 X 3.5 X 2.5 cm and 0.7 X 0.7 X 0.5 cm and 
a single lesion in the left thyroid lobe measuring 
1 X 0.7 X 0.7 cm.
Additionally, the left thyroid lobe showed a goitrous 
nodule measuring 3.7 X 3.5 X 2.5cm. The microscopic 
examination concluded a multifocal classical papillary 
carcinoma confined to the thyroid gland with no extra-
capsular extension neither lymph node involvement. 
However, four lymph nodes showed morphologic 
features of focal involvement by Langerhans cell 
histiocytosis. Immunohistochemical stains have confirmed 
these features. The Langerhans cells were positive 
for CD1a and negative for TTF-1. The thyroid gland 
was extensively examined without any morphological 
evidence of Langerhans cell histiocytosis involvement.
Four years later, the patient presented with 
anemia leukocytosis, and bone marrow biopsy showed 
marrow involvement by Langerhans cell histiocytosis 
(Figure 3). The estimated degree of involvement was 
40% with associated secondary myelofibrosis.
DISCUSSION
Langerhans cell histiocytosis (LCH) is an uncommon 
entity with unknown etiology. The question of whether 
LCH is a neoplastic or a reactive process has long been 
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debated. Evidence of clonality in LCH was reported 
more than 20 years ago, supporting the idea that 
LCH is a neoplastic process.9 Recently, the discovery of 
oncogenic BRAF V600E mutation in 25 to 64 percent of 
LCH cases has provided additional evidence that LCH 
is neoplasm.10-13 While the presence of BRAF V600E in 
LCH is associated with an increased risk of recurrence, 
there does not appear to be a correlation between 
BRAF mutation and survival time.11
LCH identification should be based on the 
histological and immunophenotypic characteristics 
of the lesion. The basic standard for the diagnosis is 
the cytological identification of the typical LCH cells 
that exhibit CD1a positivity.6,14 Additional workups 
may include detection of mutations of the BRAF-ERK 
pathway, which may provide more therapeutic options 
for refractory and recurrent diseases.6,15
It is such a rare entity in adults, making a robust 
evidence-based guideline and references lack.4 Also, 
the clinical development of LCH in adults may vary 
from self-limiting to chronic recurrent disease, which 
makes it necessary to expand studies and research on 
this group of patients.
The number of adult patients affected is likely to 
be underestimated, as specialist treatment facilities 
are rarely contacted in cases of advanced or recurrent 
disease.16 Besides, several cases are considered 
incidental, found during the investigation for other 
reasons, as shown in our two adult cases.
Papillary thyroid carcinoma (PTC) is the most 
common thyroid cancer, accounting for 80%-90% of 
thyroid carcinoma cases. It generally shows an excellent 
prognosis with a 5-year survival rate of almost 100%.17
Figure 2. Chest CT scan, A and B – axial plane- with tiny pulmonary nodules and cysts (arrows) involving both 
lungs, likely due to pulmonary Langerhans cell histiocytosis. C and D - Coronal plane - showing pulmonary cysts 
and nodules.
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Figure 3. A and B – Bone marrow biopsy with multifocal lesions composed of histiocytic cells with grooved nuclei 
admixed with multinucleated giant cells and foamy histiocytes in the background with eosinophils and plasma cells 
(20x and 40x). The histiocytic cells are immunoreactive for S100 and CD1a in C and D, respectively (40x).
Thyroid or cervical lymph node involvement by 
LCH in the presence of co-existing papillary thyroid 
carcinoma is rare; only 16 cases have been reported 
in English literature (Table 1).18-30
Two cases have been excluded; one is a child, and 
in the second case, papillary thyroid carcinoma was 
not reported.31,32 Seven cases have evidence of LCH 
in other organs, most often in the lung and pituitary 
gland. Bone involvement has been confirmed in two 
cases. The presence of lymph node involvement 
was seen in six cases. Our two cases have papillary 
thyroid carcinoma and evidence of LCH in the cervical 
lymph nodes and a second location each (lung or 
bone). LCH occurring in lymph nodes that drain solid 
malignant tumors such as melanoma and papillary 
thyroid carcinoma have been reported. However, it 
was typically associated with concomitant metastasis 
in the same lymph node.33,34,36 In fact, this will make 
the diagnosis more challenging, as cells seen in LCH 
can mimic those seen in PTC and malignant melanoma; 
moreover, both malignant melanoma and LCH 
show S100 protein-positive reaction. In both of our 
cases, there was no evidence of metastases in lymph 
nodes. One case had features of probable pulmonary 
involvement in the CT scan, and the other case also 
displayed involvement of bone and bone marrow, 
suggesting systemic disease.
Our two adult cases’ importance relies on the 
confirmation of LCH involvement of cervical lymph 
nodes without evidence of primary thyroid disease. 
Our vision is that LCH can involve the cervical lymph 
nodes as part of disseminated disease.
Additionally, several studies have shown a higher 
prevalence of hematological and solid malignancies 
among LCH patients.35,36 A study by Jennifer Ma et al.36 
of adult LCH patients found an exceptionally high 
number of additional malignancies. The identified 
malignancies were diagnosed either earlier or at the 
same time as a diagnosis of LCH, indicating that 
the cause of malignancies is not secondary to LCH 
treatment. Similarly, in our two cases, the patients 
did not receive any additional treatment, and the two 
entities appeared within a short period.
Papillary thyroid carcinoma is characterized by 
a high rate of BRAF V600E mutations.37 Yet, the 
prognostic significance of these mutations remains 
controversial.38 BRAF is a protein kinase involved in 
cellular processes, including cell survival, proliferation, 
and differentiation. The BRAF gene mutations are seen 
in many cancers, among which the BRAF V600E is the 
most common mutation.39 The association of LCH 
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with PTC can be attributed to the fact that the BRAF 
mutation may play a role in both diseases’ underlying 
pathogenesis. However, there is no sufficient available 
data regarding the BRAF mutation status in cases of 
co-existing LCH and PTC in the literature, and it is not 
available in both of our cases. Hamad et al.29 found 
BRAF V600E and BRAF V600K mutations in PTC and 
LCH tissues, respectively. While Ozisik et al.30 reported 
BRAF V600E in both PTC and LCH tissues. These two 
lesions co-exist in the thyroid gland, indicating an 
etiological relationship between the two disorders.
Isolated involvement of lymph nodes by LCH is 
rare, but spontaneous regressions have been observed. 
As a result, watch and wait in adults with LCH may 
be acceptable for isolated lymph node involvement.6,40 
Therefore, once LCH is diagnosed in a lymph node, the 
presence of other lymph node groups or pulmonary 
involvement should be investigated. This will guide 
therapeutic management strategies to such patients 
with pulmonary involvement or systemic disease.
One important finding in our cases is the ability 
to diagnose LCH on FNA. In the first case, cytological 
examination, when combined with immunohistochemistry 
on the cell-block (CB), is sufficient for confirming the 
diagnosis of Langerhans cell histiocytosis.
Our findings suggest that the emergence of other 
tumors such as papillary thyroid carcinoma should be 
expected in patients with Langerhans cell histiocytosis. 
Similarly, lymphadenopathy in patients with papillary 
thyroid carcinoma may not necessarily be a metastatic 
tumor, particularly when combined with lesions 
elsewhere in the body. In this setting, the pathological 
examination of the biopsy specimens or FNA cytology 
distinguishes between the two conditions.
CONCLUSIONS
LCH in adults is rare. Association with papillary 
thyroid carcinoma is rarely seen and should be 
considered in the presence of Langerhans cell groups 
along with PTC, whether in the thyroid gland or 
cervical lymph nodes. Once LCH has been diagnosed, 
pulmonary involvement should also be examined. This 
Table 1. Summary of the literature review of reported cases of Concomitant Langerhans cell histiocytosis and 
papillary thyroid carcinoma in adult patients
Author Gender Age
PTC and LCH in 
thyroid





N et al.18 Female 31 Yes Not described
Bone, Pituitary 
gland, Lung, Skin, 
Vagina
Safali et al.19 Male 51 Yes Yes No
Saiz et al.20 Male 43 Yes Not described No
Foulet-
Roge et al.21 Female 42 Yes Not described No
Jamaati et al. Male 24 Yes Not described Lung
Vergez et al.23 Male 29 Yes Not described Bone, Pituitary gland, Lung, Skin
Chung DH et al.24 Female 53 Yes Not described Not reported
Ceyran et al.25 Male 37 Yes Yes Not reported
Gordon et al.26 Female 23 Yes Not described Labia Vulva
Alzahrani et al.27 Female 27 Yes Yes No
Wu et al.28 Male 40 Yes Yes Lung, Liver
Hamad et al.29 Female 37 Yes Yes No
Ozisik et al.30 Male 58 Yes Not described Pituitary gland
Male 45 Yes Yes Pituitary gland, gingiva
Current Case 1 Female 49 PTC only Yes Lung
Current Case 2 Male 69 PTC only Yes Bone, bone marrow
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will direct treatment plans for patients with pulmonary 
or systemic disease involvement.
We believe that the pathologist and clinician 
need a greater understanding of LCH and its various 
clinical manifestations in adult patients to ensure that 
the diagnosis can be made.
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